课题基金 / 基金详情

Determining the Impact of SREBP on Adaptive Immunity

Determining the Impact of SREBP on Adaptive Immunity
确定 SREBP 对适应性免疫的影响
批准号:
8236263
负责人:
STEVEN J BENSINGER
金额:
$38.5万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-04-01 至 2016-03-31

项目摘要

项目成果

STEVEN J BENSINGER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): T lymphocytes are tasked with ensuring host defense against a diverse array of pathogens. They must also maintain tolerance to self-antigens to avoid autoimmunity and allergic disease. To achieve these disparate tasks, the immune system relies on a complex system of T cell proliferation, differentiation and lineage commitment. As such, understanding the fundamental mechanisms that intrinsically regulate the fate and function of an individual T cell remain important questions in immunobiology. Accumulating evidence indicates that metabolism is an important intrinsic regulator of lymphocyte function and adaptive immunity. Perturbations in the metabolic state of lymphocytes can alter T effector/helper cell function, memory T cell generation and self-tolerance. Early studies on human lymphocytes demonstrated that mitogenic signaling results in a rapid increase in de novo cholesterol and fatty acid biosynthesis. The lipid biosynthetic program precedes DNA synthesis and appears to be essential for efficient lymphocyte growth. Importantly, inhibition of the lipogenic program decreases DNA synthesis and proliferative capacity of activated lymphocytes. The molecular mechanisms underlying these striking observations have remained undefined to date. In this application, we test the hypothesis that the Sterol Response Element Binding Proteins (SREBP1 and 2), key transcriptional regulators of lipid biosynthesis and homeostasis, play a critical role in linking antigen receptor signaling with lipid metabolism, cell cycle progression and T cell fate/function. Our aims are: 1) To define the signaling pathways regulating SREBP activity and de novo lipogenesis downstream of the antigen receptor; 2) To test the hypothesis that SREBP signaling regulates cell cycle progression in activated T cells; and 3) To test the hypothesis that SREBP regulates CD8 T cell responses and immunity. The proposed studies examine a very poorly understood and potentially important aspect of lymphocyte biology. It is our expectation that these studies will increase our understanding of the crosstalk between metabolism and adaptive immunity. These studies will provide a foundation for better understanding the relationship between lipid metabolism, proliferation and differentiation in rapidly dividing hematopoietic and immune cells. PUBLIC HEALTH RELEVANCE: An important goal of immunology is elucidating the mechanisms that regulate antigen-specific immunity and autoimmunity. The experiments outlined in this proposal integrate our understanding of T cell immunobiology with current ideas regarding molecular lipid metabolism. These studies will define the relative importance of transcriptional regulation of lipid metabolism on host defense and self-tolerance, as well as elucidate the signaling pathways downstream of the antigen receptor that coordinate the lipogenic program of lymphocytes. Moreover, these studies will provide a foundation for better understanding the potential influence of lipid metabolic programs on other rapidly proliferating normal and neoplastic tissue. Given that endogenous lipids can be altered in a number of human diseases, such as dyslipidemia and atherosclerosis, our results raise the interesting possibility that molecular metabolism may impact acquired immune responses in human metabolic diseases such as dyslipidemia, obesity, diabetes and metabolic syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting host lipid metabolism to limit tissue damage in necrotizing fasciitis
CDKN2A couples lipid metabolism to ferroptosis in glioblastoma
Investigating the impact of a fatty acid-cRel inflammatory circuit in atherosclerosis
CDKN2A couples lipid metabolism to ferroptosis in glioblastoma
海外基金